metformin

Clene goes for gold, and goes public

Latest articles

Researchers identify top target for senolytic drugs

Minnesota team determines that senescent immune cells are the most dangerous type of senescent cell, making them key target for senolytic drugs. Cellular senescence is...

Prescribing exercise – the “miracle cure”

EXi targets chronic illness with digital personalised platform for prescribing exercise. British start-up EXi is making waves with its app for prescribing personalised activity programmes....

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

Sticking with glutathione could be a smart longevity choice

The body's "master antioxidant" glutathione is a powerful weapon in the fight for longevity, but it diminishes with age; AgelessRx has a range of...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
Supplement report

Editor's picks

Researchers identify top target for senolytic drugs

Minnesota team determines that senescent immune cells are the most dangerous type of senescent cell, making them key target for senolytic drugs. Cellular senescence is...

Prescribing exercise – the “miracle cure”

EXi targets chronic illness with digital personalised platform for prescribing exercise. British start-up EXi is making waves with its app for prescribing personalised activity programmes....

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...
metformin

Company targeting neurodegenerative disease with gold nanocatalyst technology goes public; multiple human trials ongoing for MS, Parkinson’s and ALS.

Salt Lake City biopharma company Clene Nanomedicine is now a publicly traded company. Clene, which has developed a new class of neuro-therapeutics called “nanocatalysts”, already has several products in Phase 2 (and one in Phase 3) trials for diseases including multiple sclerosis, Parkinson’s and amyotrophic lateral sclerosis.

Longevity.Technology: With a unique technology addressing a class of neurodegenerative disease that the World Health Organization predicts will become the second most prevalent cause of death within the next 20 years, Clene is a company on a mission to change how we treat diseases of the brain. We caught up with its CEO Rob Etherington to find out more.

Having completed a $42 million Series D financing last summer, Clene was already contemplating an IPO in 2021, when the opportunity arose to move more quickly via a SPAC (special purpose acquisition company), which saw the company go public by merging with Tottenham Acquisition I Ltd last week. The transaction raised approximately $31.9 million, and the combined, publicly-traded company operates under the name Clene Inc., with its common stock trading on the NASDAQ Capital Market under the ticker symbol “CLNN.”

“With 2020 somewhat becoming the year of the SPAC included in biotechnology… we saw this as a slightly more expeditious, slightly less onerous, slightly less expensive path to a public offering,” says Etherington.

2020 was a good year for IPOs, but it was an even better year for Special Purpose Acquisition Companies (SPACs): 242 SPACs were introduced last year.

 


 

“This capital enables us to conclude all of our clinical programs and to effectively prove whether or not we have a bioenergetic catalyst that will do what we say it does – that is neurorepair and remyelination.”

 


 

Co-founded by physicist and materials scientist, Mark Mortenson, Clene’s technology is built around his considerable expertise and experience.

“Mark had the somewhat brilliant idea to trailblaze a brand new path for the treatment of disease by taking a completely novel approach,” says Etherington. “He and his team of engineers and scientists achieved that through a completely novel application of the principles of material science, physics, and hydroelectric crystal chemistry to grow clean-surfaced metallic nanocrystals in water and use these nanocrystals to treat human diseases.”

“We have built a drug discovery platform, which means if you can think of a so-called therapeutic elemental metal used in some compound, we think we can build an oral, water-based nanotherapeutic based on such metals that may have even greater disease treating benefits.”

The idea to use elements like gold to drive medicinal efficacy has been around for hundreds of years, but Clene’s approach to using clean-surfaced metallic nanocrystals to target these conditions is, according to Etherington, completely unique.

“Clene’s basic hypothesis was to see if we could make highly faceted, clean-surfaced gold nanocrystals and used them as metabolic catalysts in various pharmaceutical applications,” he says. “Traditional approaches to making metal nanocrystals had two problems which needed to be overcome by Mark and his team, namely the lack of any positive biological results and, more importantly, inherent toxicity issues associated with surface residues left by known synthetic chemistry preparation technique.”

“We decided to test this hypothesis to see if we could improve neuroprotection, enhance remyelination, and amplify the benefits of healthy intracellular bioenergetic reactions that younger people have and take for granted.”

 


 

“These bioenergetic reactions are necessary for cells and for people to thrive, and get compromised as we age.”

 


 

The company’s bioenergetic gold-based nanocatalyst drug candidate is designed to accelerate neurorepair for patients with neurodegenerative disease. Its lead candidate, CNM-Au8, uses gold nanocrystals to amplify bioenergetic reactions in patients that ultimately drive intracellular biological reactions. Having been through years of preclinical development, Clene has concluded all of the safety and toxicity work required by regulatory agencies, and is now in a number of clinical studies.

“What we’re hoping to show in humans is exactly what we’ve already shown in animals, and that is an ability to promote neuronal repair, neural protection and remyelination,” says Etherington. “When the clinical studies wrap up, it is our hope to show that we can potentially reverse disease for patients with amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease.”

One of several Phase 2 studies underway for CNM-Au8, the Visionary MS study aims to evaluate the safety and efficacy as a remyelinating and neuro-reparative treatment in MS patients. Its primary endpoint is to assess improvement in chronic visual impairment typically seen in about half of MS patients. The company presented encouraging interim data from the study earlier this year, and expects to report on the trial’s conclusion by early 2022.

Clene is also engaged in Phase 2 trials for both MS and Parkinson’s designed to prove that CNM-Au8 is entering the body orally and then getting into the brains of patients with the diseases and driving biological energetic reactions. The company also announced positive interim results from these studies this year, with final results expected in summer next year.

 


 

“ … he goal is to build a multicenter, multi-regimen, placebo controlled Phase 3 study to evaluate the safety and efficacy of investigational products …”

 


 

For ALS, Clene has two Phase 2 trials ongoing, including one looking at preservation of motor neuron function in ALS patients. Excitingly, the company is also in a Phase 3 ALS trial called the Healey ALS Platform Trial, which is being led by Mass General Hospital. Clene is one of three companies whose products were selected from a pool of 30 to be part of the trial. If any of the three products achieve the primary endpoint of ALS functional response score, then the companies can use this data to file for a new drug application.

“The goal is to build a multicenter, multi-regimen, placebo controlled Phase 3 study to evaluate the safety and efficacy of investigational products for the treatment of ALS,” says Etherington. “This is the first platform study ever done in the neurodegenerative disease space, and the idea here is to reduce trial time, to reduce costs, and to increase patient participation.”

Image courtesy of Clene Nanomedicine

 

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
metformin

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Related articles

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

Huma’s $130m raise will scale its digital health platform

With the goal of bringing proactive, predictive care to all, Huma has $130 million financing from leading health and technology companies. The investment arms of...

Pacific AM hires healthcare manager Dani Saurymper for new fund

Pacific Asset Management has hired Dani Saurymper from AXA IM – new fund lined up for the healthcare manager. Pacific Asset Management (PAM) has announced...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...
Supps report ad middle